Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pelthos Therapeutics (PTHS) Total Current Liabilities (2024 - 2025)

Pelthos Therapeutics has reported Total Current Liabilities over the past 2 years, most recently at $26.0 million for Q4 2025.

  • Quarterly results put Total Current Liabilities at $26.0 million for Q4 2025, up 536.62% from a year ago — trailing twelve months through Dec 2025 was $26.0 million (up 536.62% YoY), and the annual figure for FY2025 was $26.0 million, up 536.62%.
  • Total Current Liabilities for Q4 2025 was $26.0 million at Pelthos Therapeutics, up from $24.8 million in the prior quarter.
  • Over the last five years, Total Current Liabilities for PTHS hit a ceiling of $26.0 million in Q4 2025 and a floor of $2.8 million in Q2 2024.